Craft

Paratek Pharmaceuticals

Stock Price

$2.2

2023-09-29

Market Capitalization

$127.8 M

2023-09-29

Revenue

$160.3 M

FY, 2022

Paratek Pharmaceuticals Summary

Company Summary

Overview
Paratek Pharmaceuticals provides solutions that enable positive outcomes and lead to positive patient stories. In the end, data isn’t remembered. It is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. The Company focuses on drugs that target infectious disease and other difficult to treat conditions.
Type
Public
Status
Active
Founded
1996
HQ
Boston, MA, US | view all locations
Website
http://paratekpharma.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Evan Loh

    Evan Loh, Chief Executive Officer, Director

  • Christine R. Coyne

    Christine R. Coyne, Senior Vice President, Commercial

  • Adam Woodrow

    Adam Woodrow, President and Chief Commercial Officer

  • Stephen Viccica, Director, Regulatory Affairs

LocationsView all

2 locations detected

  • Boston, MA HQ

    United States

    75 Park Plaza

  • King of Prussia, PA

    United States

    1000 1st Ave #400

Paratek Pharmaceuticals Financials

Summary Financials

Revenue (Q2, 2023)
$40.0M
Gross profit (Q2, 2023)
$35.6M
Net income (Q2, 2023)
($14.6M)
Cash (Q2, 2023)
$42.7M
EBIT (Q2, 2023)
($9.4M)
Enterprise value
$343.5M

Footer menu